
IHC-P analysis of human lung carcinoma using GTX81601 Interferon gamma Receptor 2 antibody, C-term.
Interferon gamma Receptor 2 antibody, C-term
GTX81601
ApplicationsFlow Cytometry, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetIFNGR2
Overview
- SupplierGeneTex
- Product NameInterferon gamma Receptor 2 antibody, C-term
- Delivery Days Customer9
- Application Supplier NoteWB: 1:1000. IHC-P: 1:50-1:100. FACS: 1:10-1:50. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID3460
- Target nameIFNGR2
- Target descriptioninterferon gamma receptor 2
- Target synonymsAF-1, IFGR2, IFNGT1, IMD28, interferon gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R-beta, IFN-gamma-R2, interferon gamma receptor accessory factor-1, interferon gamma receptor beta chain, interferon gamma transducer 1
- HostRabbit
- IsotypeIgG
- Protein IDP38484
- Protein NameInterferon gamma receptor 2
- Scientific DescriptionThis gene (IFNGR2) encodes the non-ligand-binding beta chain of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. Defects in IFNGR2 are a cause of mendelian susceptibility to mycobacterial disease (MSMD), also known as familial disseminated atypical mycobacterial infection. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance. [provided by RefSeq, Jul 2008]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Sreevalsan S, Döring M, Paszkowski-Rogacz M, et al. MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. EMBO Rep. 2020,21(12):e50155. doi: 10.15252/embr.202050155Read this paper
- Ye J, Lei J, Fang Q, et al. miR-4666-3p and miR-329 Synergistically Suppress the Stemness of Colorectal Cancer Cells via Targeting TGF-β/Smad Pathway. Front Oncol. 2019,9:1251. doi: 10.3389/fonc.2019.01251Read this paper









